|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.640 USD | -9.55% |
|
-11.62% | -43.28% |
| Mar. 12 | Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026 | CI |
| Mar. 06 | Cybin Inc. - Special Call |
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Revenues | 864K | - | - | - | - | |
Total Revenues | 864K | - | - | - | - | |
Cost of Goods Sold, Total | 1.18M | - | - | - | - | |
Gross Profit | -311K | - | - | - | - | |
Selling General & Admin Expenses, Total | 15.87M | 28.22M | 21.34M | 32.59M | 45.37M | |
Stock-Based Compensation (IS) | 11.55M | 18.03M | 4.69M | 13.89M | 42.87M | |
R&D Expenses | 3.3M | 17.59M | 25.49M | 32.36M | 54.91M | |
Other Operating Expenses, Total | 30.72M | 63.84M | 51.52M | 78.84M | 143M | |
Operating Income | -31.04M | -63.84M | -51.52M | -78.84M | -143M | |
Interest Expense, Total | -10K | - | - | - | - | |
Interest And Investment Income | 60K | 241K | 603K | 619K | 8.29M | |
Net Interest Expenses | 50K | 241K | 603K | 619K | 8.29M | |
Currency Exchange Gains (Loss) | -460K | -309K | 4.03M | 137K | 21.75M | |
Other Non Operating Income (Expenses) | - | - | - | - | -28K | |
EBT, Excl. Unusual Items | -31.44M | -63.91M | -46.89M | -78.08M | -113M | |
Gain (Loss) On Sale Of Investments | -63K | -29K | -260K | - | - | |
Other Unusual Items | -712K | -3.7M | -342K | - | - | |
EBT, Incl. Unusual Items | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Earnings From Continuing Operations | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Net Income to Company | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Net Income - (IS) | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Net Income to Common Incl Extra Items | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Net Income to Common Excl. Extra Items | -32.22M | -67.63M | -47.49M | -78.08M | -113M | |
Per Share Items | ||||||
Net EPS - Basic | -12.24 | -15.36 | -9.73 | -9.41 | -5.59 | |
Basic EPS - Continuing Operations | -12.24 | -15.36 | -9.73 | -9.41 | -5.59 | |
Basic Weighted Average Shares Outstanding | 2.63M | 4.4M | 4.88M | 8.3M | 20.22M | |
Net EPS - Diluted | -12.24 | -15.36 | -9.88 | -9.5 | -5.59 | |
Diluted EPS - Continuing Operations | -12.24 | -15.36 | -9.88 | -9.5 | -5.59 | |
Diluted Weighted Average Shares Outstanding | 2.63M | 4.4M | 4.88M | 8.3M | 20.22M | |
Normalized Basic EPS | -7.47 | -9.07 | -6 | -5.88 | -3.5 | |
Normalized Diluted EPS | -7.47 | -9.07 | -6 | -5.88 | -3.5 | |
Supplemental Items | ||||||
EBITDA | -30.99M | -63.67M | -51.28M | -78.58M | -143M | |
EBITA | -31.04M | -63.84M | -51.5M | -78.8M | -143M | |
EBIT | -31.04M | -63.84M | -51.52M | -78.84M | -143M | |
Normalized Net Income | -19.65M | -39.94M | -29.3M | -48.8M | -70.71M | |
Interest on Long-Term Debt | - | - | - | 8K | 7K | |
Supplemental Operating Expense Items | ||||||
Advertising Expense | - | - | - | - | - | |
Marketing Expenses | 4.94M | 3.69M | 1.54M | 2.79M | 6.59M | |
Selling and Marketing Expenses | 4.94M | 3.69M | 1.54M | 2.79M | 6.59M | |
General and Administrative Expenses | 10.92M | 24.53M | 19.81M | 29.8M | 38.78M | |
Research And Development Expense From Footnotes | 3.3M | 17.59M | 25.49M | 32.36M | 54.91M | |
Stock-Based Comp., Other (Total) | 11.58M | 18.03M | 4.69M | 13.89M | 42.87M | |
Total Stock-Based Compensation | 11.58M | 18.03M | 4.69M | 13.89M | 42.87M |
- Stock Market
- Equities
- HELP Stock
- Financials Cybin Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
